Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

January 11, 2024

Study Completion Date

January 11, 2024

Conditions

Leishmaniasis

Interventions

DRUG

GSK3494245

Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

DRUG

Placebo

Matching placebo capsules will be provided

Trial Locations (1)

GSK Investigational Site, Cambridge